A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
This research study, called ACCLAIM-Lp(a), is testing a new medication called lepodisiran. The main goal is to see if lepodisiran can lower the risk of serious heart problems, like heart attacks and strokes, in adults who have high levels of a type of fat in their blood called lipoprotein(a) (Lp(a)). Participants selected for this study either already have heart disease or are at a high risk of developing it. The study drug will be given as an injection just under the skin. We're also looking to enrol more people to understand how different ways of giving the drug might affect Lp(a) levels. This is a Phase 3 trial, meaning it's one of the final steps before a drug might be considered for wider use.
En un coup d'œil
De quoi parle cette étude ?
This important research study, called ACCLAIM-Lp(a), is investigating a new medication called lepodisiran. The main purpose is to find out if this medicine can help lower the risk of serious heart and blood vessel problems, such as heart attacks and strokes, in people who have particularly high levels of a substance in their blood called lipoprotein(a), often shortened to Lp(a).
Lp(a) is a type of fat and protein found in your blood, and high levels of it have been linked to an increased risk of heart disease. While there are treatments for other types of cholesterol, there aren't many specific treatments for high Lp(a) yet. That's why this study is so important — it's exploring a new way to potentially protect people from future heart and stroke events.
The study will involve adults who either already have heart or blood vessel disease (like after a heart attack or needing a procedure to open blocked arteries) or who are considered at high risk of having a heart attack or stroke. Participants will be given the study medication, lepodisiran, as an injection under the skin. Another part of the study will involve additional participants to explore if giving the medicine in different ways can also effectively lower Lp(a) levels.
Points clés
- This study tests a new drug, lepodisiran, for high lipoprotein(a).
- It aims to lower the risk of heart attacks and strokes.
- It's for adults with existing heart disease or those at high risk.
- The drug is given as an injection under the skin.
- Participation involves regular clinic visits and health monitoring.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To join this study, you would need to meet certain requirements. Firstly, you must be 18 years or older and have a high level of lipoprotein(a) (Lp(a)) in your blood, specifically 175 nanomoles per litre or higher.
Secondly, you must either have existing heart or blood vessel disease (like heart disease or blockages in arteries) that has caused an event (like a heart attack) or required a procedure. Alternatively, if you are 55 years or older, you might be eligible if you are at high risk of a first heart attack or stroke. This could include having a known history of conditions like coronary artery disease, narrowing of major arteries, or blocked arteries in your legs, even if you haven't had an event yet. It could also apply if you have a family history of very high cholesterol (familial hypercholesteremia) or a combination of several other risk factors.
However, some conditions would mean you cannot take part. For example, if you've had a recent major heart event or surgery in the past two months, have very high blood pressure that isn't under control, severe heart failure, or have had a specific blood treatment called lipoprotein apheresis recently. Also, people with serious kidney or liver problems would not be suitable for this study.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have high lipoprotein(a) (Lp(a)) levels of 175 nmol/L or higher?
- Have you had a heart attack, stroke, or a procedure for blocked arteries, OR are you 55 or older with other heart risk factors?
- Have you NOT had a major heart event or surgery in the past 2 months?
- Do you have well-controlled blood pressure?
- Do you NOT have severe problems with your kidneys or liver?
En quoi consiste la participation ?
Taking part in this study would involve regularly visiting a clinic for health checks and to receive the study medication. This medicine, lepodisiran, will be given as an injection just under your skin. You will either receive the active drug or a placebo (a dummy drug with no active ingredients). This is decided randomly, like flipping a coin, and neither you nor your study doctor will know which you are receiving. The study team will monitor your health closely, including taking blood samples to check your Lp(a) levels and overall health. They will also keep track of any changes in your health or any new symptoms you experience. The total duration of your participation in the study, including all follow-up, will be discussed in detail by the study team.
Risques et avantages potentiels
Locations (928)
- Birmingham Clinical ResearchCode postal vérifiéBirmingham, États-Unis
- Alliance for Multispecialty Research, LLCCode postal vérifiéDaphne, United States
- SEC Clinical ResearchCode postal vérifiéDothan, United States
- Alliance for Multispecialty Research, LLCCode postal vérifiéMobile, États-Unis
- Mobile Heart SpecialistsCode postal vérifiéMobile, États-Unis
- Groupe Médical Prime, LLC faisant affaire sous le nom de Centre Gilbert pour la Médecine Familiale, LLCCode postal vérifiéGilbert, États-Unis
- Mercy Gilbert Medical CenterCode postal vérifiéGilbert, États-Unis
- Sun City Clinical ResearchCode postal vérifiéGlendale, United States
- Elite Clinical Studies, LLCCode postal vérifiéPhoenix, États-Unis
- Helios Clinical Research - PhoenixCode postal vérifiéPhoenix, États-Unis
- Absolute Clinical ResearchCode postal vérifiéPhoenix, États-Unis
- Institut de Recherche Clinique de l'Arizona (CRI) - Sun City WestCode postal vérifiéSun City West, États-Unis
Questions fréquentes
What is lipoprotein(a)?
Lipoprotein(a), or Lp(a), is a type of fat and protein particle in your blood. High levels of Lp(a) are linked to a higher risk of heart disease and stroke.
Pourquoi cette étude est-elle importante ?
This study is important because there are currently limited treatments specifically for high Lp(a). It aims to find a new way to reduce heart disease and stroke risk.
What is a Phase 3 study?
A Phase 3 study is one of the final stages of clinical research. It involves a larger number of people to confirm the safety and effectiveness of a new drug before it can be considered for general use.
Qu'est-ce qu'un placebo ?
A placebo is a 'dummy' treatment that looks just like the study drug but has no active ingredients. It helps researchers compare the effects of the active drug to no treatment.
Will I know if I'm getting the actual drug or the placebo?
No, during the main part of the study, neither you nor your study doctor will know whether you are receiving the active drug or the placebo. This helps ensure unbiased results.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.